Business
2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement
COPENHAGEN, Denmark - August 20, 2025. Novonesis today announces its ‘GROW’ strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant re-investments to secure long-term growth. By 2030, the company expects to deliver an organic sales CAGR of 6-9%, an adjusted EBITDA margin of ~39% and an adjusted ROIC excl. goodwill of ~16%. Novonesis is well positioned to continue to drive strong performance in biosolutions. The company is
About this update from Novonesis A/s Class B
[{"type":"image","alt":"Novonesis (Novozymes A/S)","displaySize":"","headline":null,"caption":"Novonesis (Novozymes A/S)","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":38,"url":"https://media.zenfs.com/en/globenewswire.com/d587064c2241c08df4f2bac0e72e38fb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zKklvML9_v1QAJVxEtCwVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/d587064c2241c08df4f2bac0e72e38fb","width":300,"height":38}},"lazy":false},{"type":"text","content":"COPENHAGEN, Denmark - August 20, 2025. Novonesis today announces its ‘GROW’ strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant re-investments to secure long-term growth. By 2030, the company expects to deliver an organic sales CAGR of 6-9%, an adjusted EBITDA margin of ~39% and an adjusted ROIC excl. goodwill of ~16%.","length":399,"tagName":"p"},{"type":"text","content":"Novonesis is well positioned to continue to drive strong performance in biosolutions. The company is present across multiple end-markets with strong capabilities to deliver value-adding solutions for tailored customer needs. Novonesis’ distinct position is built on three capabilities: deep customer understanding, unparalleled innovation and an exceptional ability to scale and produce robust and affordable biosolutions. In a world with a growing population, increasing energy needs, evolving nutritional and health trends, as well as climate risks, the company sees a strong and increasing demand for biosolutions.","length":617,"tagName":"p"},{"type":"text","content":"Ester Baiget, President & CEO: “We are clearly on track to deliver on our 2025 targets that were set when we announced the combination. The potential for biosolutions continues to be strong and Novonesis is uniquely positioned to achieve accelerated profitable growth towards 2030 and beyond. We focus on growing our core, where we continue to see strong demand, and we significantly invest in our distinct capabilities to further expand our market and innovation leadership. We believe the more we grow, the more long-term value and impact we create for shareholders, customers, people and the planet.” ","length":613,"tagName":"p"},{"type":"text","content":"Novonesis’ proven growth matrix ...